Magnesium and Dexmedetomidine in Pheochromocytoma

Istanbul University

Status: Completed

Conditions: Hemodynamic Instability; Phaeochromocytoma Crisis

Treatments: Drug: Magnesium-Dexmedetomidine

Study type: Observational

Funder types: Other

Identifiers

NCT05102058

2021/42

Details and patient eligibility

About

Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration between the group treated with magnesium-dexmedetomidine and conventional group in pheochromocytoma.

Enrollment: 108 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• American Society of Anesthesiologists classification (ASA) 1-3
• high urinary catecholamine or metabolites
• tumor sizes < 5 cm
• body mass index (BMI) <35 kg/m2

Exclusion criteria

• open surgery
• bilateral masses
• tumor larger than 5 cm
• incomplete data

Trial design

108 participants in 2 patient groups

Conventional group (GC)

Description:

Not receive perioperative additional medication.

Magnesium-dexmedetomidine therapy group (GMD)

Description:

Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively.

Treatment:

Drug: Magnesium-Dexmedetomidine